Senior Leadership Team

Tim Kelly

Tim Kelly, PhD

President & CEO

Tim began his tenure at KBI in 2005, originally acting as Vice President of Biopharmaceutical Development, where he led the establishment and growth of KBI's analytical...

Kathy Lee

Kathy S. Lee

Senior VP, Quality & Regulatory

Kathy is highly experienced in quality management and compliance for biopharmaceutical development and production. 

Carnley Norman

Carnley Norman, Ph.D.

VP, Manufacturing Operations, Durham, NC

Carnley has over 18 years of therapeutic protein and vaccine drug substance process development, characterization, technology transfer...

6ca5ce33e14e05c58a37a7746370694f

Sigma Mostafa

VP, Process Development

Sigma has nearly 20 years of experience in process development, process characterization and validation, and manufacturing of therapeutic proteins. 

Wayne Yount

Wayne Yount, Ph.D.

VP, Biopharmaceutical Development, NC

Wayne joined KBI in 2005 as a member of the Biopharmaceutical Development team. Since that time he has focused on the establishment and growth...

Stewart McNaull

Stewart McNaull, Ph.D.

Senior VP, Business Development

Stewart has nearly 20 years of experience in biopharmaceutical process development and manufacturing with a focus towards driving technology...

Bob Todd

Bob Todd

VP, Process Development, Boulder

Bob has over 25 years of experience in the development of processes for biotherapeutic products. Prior to joining KBI, Bob was a Director of Process...

Dirk Lange

Dirk T. Lange

Senior VP, Operations, Boulder

Dirk has more than 16 years of experience in Biopharmaceutical Development, Manufacturing and Business Development. Prior to returning to KBI, he was Head...

Don Healy-1

Don Healey, Ph.D.

Senior VP, Operations, The Woodlands

Don has over 30 years experience in cellular immunology and immune regulation in both academic and biotech environments. Prior to joining KBI...

Rachel Mandell

Rachel Mandell

VP and General Counsel

Rachel has over 20 years of experience as a corporate attorney. In her previous role as Director, Legal at Lord Corporation, Rachel advised the business on...

Dan Povia

Dan Povia

VP, Finance

Dan is a seasoned executive with over 30 years of work experience in financial and operational controls, financial reporting and forecasting risk management, audit and...

Tom Milici

Thomas Milici

VP, Engineering

Tom has over 20 years of experience in the design, construction and operation of large scale GMP production facilities. Prior to joining KBI, Tom held the position of VP...

Joint Scientific Advisory Board

Joint Scientific Advisory Board formed with Selexis SA - View Press Release

John F. Carpenter, Ph.D.

Dr. Carpenter is Professor of Pharmaceutical Sciences at the University of Colorado School of Pharmacy, and a co-founder and co-director of the University of Colorado Center for Pharmaceutical Biotechnology. His research interests include mechanisms for protein degradation and stabilization in pharmaceutical formulations during bioprocessing and in delivery systems. Also, he has worked for several years to define rational strategies for stabilizing proteins and vaccines during freeze-drying and storage in the dried solid. He has published more than 280 peer-reviewed papers and is an inventor on more than 30 issued patents. He is editor for reviews and commentaries for Journal of Pharmaceutical Sciences. Dr. Carpenter serves on the editorial advisory boards for Pharmaceutical Research, The AAPS Journal, Journal of Pharmaceutical Sciences, Current Pharmaceutical Biotechnology, Molecular Pharmaceutics and BioPharm International. He has received several teaching awards and The Ebert Prize. He is a fellow of the American Association for Advancement of Science (AAS), the American Association of Pharmaceutical Scientists (AAPS) and the National Academy of Inventors. He has received the AAPS Research Achievement Award in Biotechnology. Dr. Carpenter also is the organizer of the Colorado Protein Stability Conferences. 

Cori Gorman, Ph.D.

Dr. Gorman has 30 years of experience in the biotechnology industry, including six years as CEO/chairman of BioXpress Therapeutics SA. She is currently Vice President of Precision Medicine and Manufacturing at Agenus, where she leads the effort in developing individualized cancer vaccines. She has helped early-stage biotechnology companies raise more than $80 million and has closed more than 35 partnerships. During her tenure at Genentech, Dr. Gorman helped develop several marketed products including Kogenate®, Activase®, Herceptin®, Xolair®, Raptiva®, Avastin® and Perjeta®. The total sales of these marketed therapeutics exceed $15 billion. She is an inventor on nine issued patents in the fields of gene expression and delivery and gene therapy Her scientific work has received over 21,000 citations. Dr. Gorman has received several fellowships from such organizations as the American Cancer Society, the National Cancer Institute, the European Molecular Biology Organization and NATO.

Steven M. Cramer, Ph.D.

Dr. Cramer is the William Weightman Walker Professor at Rensselaer Polytechnic Institute and is known for his contributions to the separation of complex biological products and the development of chromatographic materials, processes and predictive tools for enabling their biomanufacturing. In addition, he has made seminal contributions to the molecular understanding of the interactions that create unique selectivities in these separation systems. His lab is currently conducting research on several areas related to protein-surface interactions including prediction of protein binding affinity and multiscale modeling of chromatographic systems, development of efficient antibody and bispecific antibody separation systems, fundamental studies in multimodal chromatography, multilevel automated peptide synthesis/screening system for design of affinity peptides, smart biopolymer affinity precipitation systems, biophysics of protein interactions with surfaces, ligands and proteins, platformable strategies for effective removal of process HCPs and integrated semi-continuous biomanufacturing processes. He was the editor of Separation Science and Technology for 20 years and has been awarded the Alan S. Michaels Award for the Recovery of Biological Products (ACS Division of Biochemical Technology) and the ACS National Award in Separation Science and Technology. He was also awarded Rensselaer’s Early Career Award as well as the School of Engineering Outstanding Professor and Research Excellence Awards. Dr. Cramer has been elected a fellow of the American Association for the Advancement of Science, American Institute of Chemical Engineers, the American Chemical Society and the American Institute for Medical and Biological Engineering. 

Michael J. Betenbaugh, Ph.D.

Dr. Betenbaugh, an independent consultant as well as professor of chemical and biomolecular engineering and lead principal investigator of the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC) at Johns Hopkins University, is known for integrating systems biology with cellular, metabolic and biochemical engineering for eukaryotic biotechnology applications. Dr. Betenbaugh is one of the original pioneers of eukaryotic metabolic engineering and has made multiple landmark contributions in improving the efficiency and effectiveness of mammalian and insect production hosts, in fundamental discoveries in glycobiology, in applying systems biology to understand mammalian cells in biotechnology and biomedicine and in advancing knowledge about sustainable algal bioprocessing for biofuels and other products. Dr. Betenbaugh’s most significant achievements include the application of chaperones and foldases to increase protein folding and product yields from insect cells; glycoengineering in insect and mammalian hosts to produce sialylated high-value glycoproteins; anti-apoptosis engineering to increase mammalian survival and productivity; genomics, proteomics, glycomics, and systems biology models of mammalian hosts; microRNA analysis and genome engineering in mammalian cells; and advancing sustainable microalgae processing. Dr. Betenbaugh’s group was the first to undertake whole pathway metabolic engineering to overcome glycosylation bottlenecks in one of the first projects funded as part of National Science Foundation’s Metabolic Engineering Program, a forerunner to current synthetic biology efforts. His group was also one of the first to demonstrate apoptosis activation in industrial cell culture processes and is the world leader in controlling programmed death in cell culture processes. Dr. Betenbaugh received the D.I.C. Wang Award for Excellence in Biochemical Engineering (2017), the Marvin J. Johnson (2015) and James Van Lanen awards from the American Chemical Society’s Division of Biochemical Technology and the Cell Culture Engineering Award (2010). He served as a visiting scientist at the Kyoto Institute of Technology in 2001 and is an elected fellow of the American Institute for Medical and Biological Engineering (AIMBE).